Atomized Inhalation ICG for Treatment of Congenital Lung Malformations

Launched by JIEXIONG FENG · Mar 8, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment method for children with certain congenital lung conditions, specifically focusing on a technique called aerosol inhalation of a special dye known as Indocyanine Green (ICG). The study aims to determine how safe and effective this approach is when used before a type of surgery called thoracoscopic resection, which helps remove the abnormal lung tissue. Essentially, researchers want to see if this inhalation can help doctors accurately find and remove lung malformations in children.

To participate in this trial, children must be diagnosed with congenital lung malformations through imaging tests like CT or MRI scans. Eligible participants are those aged between 3 months and 14 years, and those with complicated life-threatening diseases or severe lung infections are not eligible. If children join the study, they can expect to receive the inhalation treatment and then undergo surgery, with careful monitoring to ensure their safety throughout the process. This trial is currently looking for participants, and it could provide valuable information to improve treatments for children with these lung issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • children with congenital lung malformations diagnosed by CT or MRI scan
• Exclusion Criteria:
• • 1. ages \<3 months and \>14 years 2. complicated other life-threatening disease; 3. complicated severely pulmonary infection